Pre-earnings options volume in Xenon Pharmaceuticals (XENE) is normal with calls leading puts 14:1. Implied volatility suggests the market is anticipating a move near 24.8%, or 0c, after results are released. Median move over the past eight quarters is 4.0%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Is XENE a Buy, Before Earnings?
- Xenon Pharmaceuticals initiated with an Outperform at Wolfe Research
- Xenon Pharmaceuticals price target raised to $66 from $60 at Stifel
- Xenon Pharmaceuticals Issues Inducement Stock Options to New Hires
- Xenon Pharmaceuticals: Undervalued ‘Pipeline-in-a-Drug’ Story with Blockbuster Potential Ahead of Key 2026 Readouts